AU2006256891B2 - Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection - Google Patents

Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection Download PDF

Info

Publication number
AU2006256891B2
AU2006256891B2 AU2006256891A AU2006256891A AU2006256891B2 AU 2006256891 B2 AU2006256891 B2 AU 2006256891B2 AU 2006256891 A AU2006256891 A AU 2006256891A AU 2006256891 A AU2006256891 A AU 2006256891A AU 2006256891 B2 AU2006256891 B2 AU 2006256891B2
Authority
AU
Australia
Prior art keywords
autoimmune
disease
ides
syndrome
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006256891A
Other languages
English (en)
Other versions
AU2006256891A1 (en
Inventor
Lars Bjorck
Rikard Holmdahl
Kutty Selva Nandakumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of AU2006256891A1 publication Critical patent/AU2006256891A1/en
Application granted granted Critical
Publication of AU2006256891B2 publication Critical patent/AU2006256891B2/en
Assigned to Hansa Biopharma AB reassignment Hansa Biopharma AB Request to Amend Deed and Register Assignors: HANSA MEDICAL AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006256891A 2005-06-09 2006-06-08 Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection Active AU2006256891B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0511769.2 2005-06-09
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment
GB0605781.4 2006-03-22
PCT/EP2006/005454 WO2006131347A2 (en) 2005-06-09 2006-06-08 Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Publications (2)

Publication Number Publication Date
AU2006256891A1 AU2006256891A1 (en) 2006-12-14
AU2006256891B2 true AU2006256891B2 (en) 2011-08-04

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006256891A Active AU2006256891B2 (en) 2005-06-09 2006-06-08 Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Country Status (14)

Country Link
US (1) US8133483B2 (cg-RX-API-DMAC7.html)
EP (1) EP1901773B1 (cg-RX-API-DMAC7.html)
JP (1) JP5427409B2 (cg-RX-API-DMAC7.html)
CN (1) CN105770871A (cg-RX-API-DMAC7.html)
AT (1) ATE548049T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006256891B2 (cg-RX-API-DMAC7.html)
BE (1) BE2021C505I2 (cg-RX-API-DMAC7.html)
CA (1) CA2611646C (cg-RX-API-DMAC7.html)
ES (1) ES2380950T3 (cg-RX-API-DMAC7.html)
FR (1) FR21C1004I2 (cg-RX-API-DMAC7.html)
NL (1) NL301089I2 (cg-RX-API-DMAC7.html)
PL (1) PL1901773T3 (cg-RX-API-DMAC7.html)
PT (1) PT1901773E (cg-RX-API-DMAC7.html)
WO (1) WO2006131347A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216863B8 (en) * 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
US8691544B2 (en) 2007-05-04 2014-04-08 Glycorex Transplantation Ab Material for separation of a biomolecule
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
ES2535963T3 (es) 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
US8673606B2 (en) * 2009-04-22 2014-03-18 Ofir Menashe Microorganism comprising particles and uses of same
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
SG11201806639VA (en) 2016-02-04 2018-09-27 Genovis Ab New streptococcal proteases
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP7668261B2 (ja) * 2019-08-01 2025-04-24 メモリアル スローン ケタリング キャンサー センター 改良された免疫療法のための細胞およびその使用
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
JP2023541698A (ja) * 2020-09-21 2023-10-03 上海宝済薬業有限公司 組合せ医薬及びその使用
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
JP2024547125A (ja) * 2021-12-22 2024-12-26 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
KR20250123949A (ko) 2022-11-18 2025-08-18 사이즈믹 테라퓨틱, 인코포레이티드. Fc 융합 분자 및 이의 용도
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051914A2 (en) * 2001-12-18 2003-06-26 Hansa Medical Research Aktiebolag Ides, an igg-degrading enzyme of streptococcus pyogenes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261585B2 (en) * 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051914A2 (en) * 2001-12-18 2003-06-26 Hansa Medical Research Aktiebolag Ides, an igg-degrading enzyme of streptococcus pyogenes

Also Published As

Publication number Publication date
PT1901773E (pt) 2012-06-06
PL1901773T3 (pl) 2012-09-28
US8133483B2 (en) 2012-03-13
EP1901773B1 (en) 2012-03-07
FR21C1004I1 (cg-RX-API-DMAC7.html) 2021-03-26
WO2006131347A3 (en) 2007-05-31
CN105770871A (zh) 2016-07-20
JP5427409B2 (ja) 2014-02-26
FR21C1004I2 (fr) 2022-01-14
EP1901773A2 (en) 2008-03-26
US20100303781A1 (en) 2010-12-02
BE2021C505I2 (cg-RX-API-DMAC7.html) 2021-05-31
NL301089I2 (nl) 2021-02-04
ES2380950T3 (es) 2012-05-21
WO2006131347A2 (en) 2006-12-14
JP2008542418A (ja) 2008-11-27
CA2611646C (en) 2015-08-11
ATE548049T1 (de) 2012-03-15
NL301089I1 (cg-RX-API-DMAC7.html) 2021-01-20
AU2006256891A1 (en) 2006-12-14
CA2611646A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
AU2006256891B2 (en) Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
AU2007331736B2 (en) Use of the endoglycosidase EndoS for treating immunoglobulin G mediated diseases
EP3668972B1 (en) Engineered dnase enzymes and use in therapy
CN101232900B (zh) IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
JPH11253179A (ja) 新規グルコサミニダ―ゼ
JPH07149654A (ja) アンギオゲニンの抑制剤
JPH1189585A (ja) 新規Ｄｅｆ１
JPH11266880A (ja) 新規ｄｂｐＡ
JPH11337548A (ja) 新規ＤｂｐＢ
US6524814B1 (en) Enzyme and DNA sequence encoding krill-derived multifunctional protein
US20230233652A1 (en) 28 kda gst proteins from schistosoma for the treatment of vasculitis
JP2001523114A (ja) スタフィロコッカス・アウレウス由来の３−ヒドロキシアシル−ｃｏａデヒドロゲナーゼ
WO2008024457A2 (en) Rnase a peptides, fragments and uses thereof
JPH11137277A (ja) 新規ｇｒｅＡ
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
JPH1175877A (ja) 新規化合物
WO2019025782A1 (en) POLYPEPTIDES OF AND USES THEREOF
JPH1198991A (ja) 新規化合物
JPH11235182A (ja) 新規化合物
JP2001516211A (ja) スタフィロコッカスの３−デヒドロキネートシンターゼ
JPH11253172A (ja) ＭｅｃＢ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: HANSA BIOPHARMA AB

Free format text: FORMER NAME(S): HANSA MEDICAL AB